ONT.L

Healthcare Biotechnology

Oxford Nanopore Technologies plc

£220.60
-10.20 -4.42% today

Price History

Not enough data

Key Stats

Market Cap
215.85B
Avg Volume
2.67M
EPS
-£0.13
52W High
£238.80
Div. Yield
0.0%

Analyst Ratings

Buy
4
Str Buy
6
Buy
2
Hold
0
Sell
0
Str Sell

Valuation

Forward P/E
-30.47
P/B Ratio
5.07
P/S Ratio
9.18
EV/EBITDA
-22.81
EV/Revenue
8.97

Margins

Gross Margin 62.8%
Operating Margin (43.4%)
Net Margin (51.7%)
EBITDA Margin (39.3%)

Growth & Returns

Revenue Growth (YoY)
10.5%
Return on Equity
(25.6%)
Return on Assets
(10.9%)

Liquidity & Leverage

Current Ratio
3.52
Quick Ratio
2.73
Debt / Equity
0.10
Total Cash
184.80M
Total Debt
41.80M

About

Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows analysis of DNA or RNA. The company offers MinION Mk 1D, a portable device for DNA and RNA sequencing; and GridION and GridION Q, a compact bench top device that delivers a version of hardware, software, and chemistry. It also provides PromethION products, such as PromethION 2, PromethION 24, and PromethION 48. The company has a collaboration with Cepheid to develop and commercialize automated infectious disease sequencing solutions. It operates in the region of Americas, Europe, the Middle East, Africa, India, and the Asia Pacific. The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies plc in May 2008. Oxford Nanopore Technologies plc was incorporated in 2005 and is headquartered in Oxford, the United Kingdom.

nanoporetech.com